Medical AI & SaMD

FDA-MHRA AI SaMD review path clarifies the export route for qualified Chinese firms, highlighting PCCP readiness, faster dual-market planning, and lower importer compliance risk.

FDA opens a faster remote review path for SaMD exports, cutting review cycles to 45 working days. See how AI imaging, digital pathology, and remote monitoring firms can gain faster U.S. market access.

FDA remote review update clarifies the China SaMD export path. Learn how FDA 510(k), De Novo, audit logs, and cross-border data mapping may speed U.S. market entry.

Digital therapeutics cost explained: uncover licensing, compliance, integration, and patient support factors that drive total spend, so you can compare vendors smarter and control ROI.

FDA SaMD review update clarifies the export path for China AI medtech, covering remote validation, cloud PACS/VNA, RWD, traceability, and audit readiness for faster global market entry.